Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 4

2(50.0%)

4Total

N/A(2)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00955955Phase 4Completed

Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder

Role: collaborator

NCT00933998Not ApplicableCompleted

Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®

Role: collaborator

NCT01247558Completed

Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy

Role: lead

NCT01503892Not ApplicableUnknown

Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics

Role: collaborator

NCT01368549Unknown

Metanx® P.L.U.S. Program (Progress Through Learning, Understanding & Support)

Role: lead

NCT01193192Terminated

A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

Role: lead

NCT00321152Phase 4Completed

A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)

Role: collaborator

All 7 trials loaded